- Conditions
- Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma
- Interventions
- Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 204
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Multiple Myeloma
- Interventions
- ACY-1215 in combination with pomalidomide and dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Dallas, Texas • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Multiple Myeloma
- Interventions
- ABBV-838, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 2 more
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse
- Interventions
- Ixazomib, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Omar Nadeem, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Carfilzomib, Daratumumab SC, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Pueblo, Colorado • Detroit, Michigan + 7 more
- Conditions
- Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
- Interventions
- ixazomib citrate, dexamethasone, pomalidomide
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Dexamethasone
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more
- Conditions
- Skin Kaposi Sarcoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pomalidomide, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • Miami, Florida • Chicago, Illinois + 9 more
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- pomalidomide, ixazomib, dexamethasone
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 336
- States / cities
- Anchorage, Alaska • Burbank, California • La Jolla, California + 237 more
- Conditions
- Multiple Myeloma
- Interventions
- pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Plasma Cell Myeloma
- Interventions
- isatuximab SAR650984, Pomalidomide, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Fullerton, California • San Francisco, California + 21 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab Mafodotin, Nirogacestat, Pomalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Clinical Pharmacology, Healthy Volunteer Study
- Interventions
- Placebo, Pomalidomide, Moxifloxacin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL
- Interventions
- Nivolumab, Pomalidomide
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Los Alamitos, California • Torrance, California • Whittier, California + 9 more
- Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • New York, New York • Columbus, Ohio + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- CC-4047
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Summit, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- No City Provided, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan, Prednisone, Cyclophosphamide, Dexamethasone, Ascorbic acid, PLD, Lenalidomide, Pomalidomide
- Drug · Dietary Supplement
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 12
- States / cities
- Bakersfield, California • Concord, California • Encinitas, California + 9 more
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- pomalidomide, dexamethasone, rituximab
- Drug
- Lead sponsor
- Steven P. Treon, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more